Supernus Pharmaceuticals (SUPN)
(Delayed Data from NSDQ)
$29.95 USD
+0.22 (0.72%)
Updated Apr 23, 2024 04:00 PM ET
After-Market: $29.98 +0.03 (0.10%) 7:58 PM ET
5-Strong Sell of 5 5
D Value D Growth D Momentum D VGM
Supernus Pharmaceuticals (SUPN) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$40.50 | $43.00 | $38.00 | 36.32% |
Price Target
Based on short-term price targets offered by four analysts, the average price target for Supernus Pharmaceuticals comes to $40.50. The forecasts range from a low of $38.00 to a high of $43.00. The average price target represents an increase of 36.32% from the last closing price of $29.71.
Analyst Price Targets (4 )
Broker Rating
Supernus Pharmaceuticals currently has an average brokerage recommendation (ABR) of 1.50 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by four brokerage firms. The current ABR compares to an ABR of 1.50 a month ago based on four recommendations.
Of the four recommendations deriving the current ABR, three are Strong Buy, representing 75% of all recommendations. A month ago, Strong Buy represented 75%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 3 | 3 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.50 | 1.50 | 1.50 | 1.50 | 1.50 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
2/28/2024 | Piper Sandler | David Amsellem | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.50 |
ABR (Last week) | 1.50 |
# of Recs in ABR | 4 |
Average Target Price | $40.50 |
LT Growth Rate | NA |
Industry | Medical - Generic Drugs |
Industry Rank by ABR | 179 of 252 |
Current Quarter EPS Est: | 0.39 |